Caris Life Sciences, Inc.
CAI
$27.25
-$0.75-2.68%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Net Income | 7.61% | ||||
| Total Depreciation and Amortization | -60.21% | ||||
| Total Amortization of Deferred Charges | 22.33% | ||||
| Total Other Non-Cash Items | 157.65% | ||||
| Change in Net Operating Assets | 1,225.08% | ||||
| Cash from Operations | 57.61% | ||||
| Capital Expenditure | -54.72% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -104.51% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | 72.50% | ||||
| Issuance of Common Stock | 582.86% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | -99.36% | ||||
| Foreign Exchange rate Adjustments | 300.00% | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -117.62% | ||||